Key clinical point: Bromodomain-containing protein 4 (BRD4) inhibitors are possible future treatment candidates for mantle cell lymphoma (MCL).
Major finding: Treatment with the BRD4 inhibitor I-BET151 had a dose-dependent inhibitory effect on cell proliferation in MCL cell lines.
Study details: Researchers performed gene expression profiling and chromatin immunoprecipitation with parallel sequencing for BRD4.
Disclosures: The researchers reported having no conflicts of interest.
Tsukamoto T et al. Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):77-89.